GrippeCanadaV3, Main, Exploration, bibRecord, 000152

Fluzone® High-Dose Influenza Vaccine.

Identifieur interne : 000152 ( Main/Exploration ); précédent : 000151; suivant : 000153

Fluzone® High-Dose Influenza Vaccine.

Auteurs : Corwin A. Robertson [États-Unis] ; Carlos A. Diazgranados [États-Unis] ; Michael D. Decker [États-Unis] ; Ayman Chit [États-Unis, Canada] ; Monica Mercer [États-Unis] ; David P. Greenberg [États-Unis]

Source :

Expert review of vaccines [ 1744-8395 ] ; 2016.

RBID : pubmed:27813430

Descripteurs français

KwdFr :
- Adulte d'âge moyen, Analyse coût-bénéfice, Anticorps antiviraux (sang), Canada, Grippe humaine (), Hospitalisation, Humains, Sujet âgé, Sujet âgé de 80 ans ou plus, Surveillance post-commercialisation des produits de santé, Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (immunologie), Vaccins antigrippaux (économie), États-Unis d'Amérique.
MESH :
- administration et posologie : Vaccins antigrippaux.
- effets indésirables : Vaccins antigrippaux.
- immunologie : Vaccins antigrippaux.
- sang : Anticorps antiviraux.
- économie : Vaccins antigrippaux.
- Adulte d'âge moyen, Analyse coût-bénéfice, Canada, Grippe humaine, Hospitalisation, Humains, Sujet âgé, Sujet âgé de 80 ans ou plus, Surveillance post-commercialisation des produits de santé, États-Unis d'Amérique.

English descriptors

KwdEn :
- Aged, Aged, 80 and over, Antibodies, Viral (blood), Canada, Cost-Benefit Analysis, Hospitalization, Humans, Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza Vaccines (economics), Influenza Vaccines (immunology), Influenza, Human (prevention & control), Middle Aged, Product Surveillance, Postmarketing, United States.
MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , adverse effects : Influenza Vaccines.
- chemical , blood : Antibodies, Viral.
- chemical , economics : Influenza Vaccines.
- chemical , immunology : Influenza Vaccines.
- prevention & control : Influenza, Human.
- Aged, Aged, 80 and over, Canada, Cost-Benefit Analysis, Hospitalization, Humans, Middle Aged, Product Surveillance, Postmarketing, United States.

Abstract

INTRODUCTION

Fluzone® High-Dose (IIV3-HD) is a trivalent, inactivated, split-virus influenza vaccine indicated for use in older adults (≥65 years of age). It contains 60 µg hemagglutinin of each influenza strain, which is four times the hemagglutinin content of standard-dose influenza vaccines, including Fluzone (IIV3-SD). IIV3-HD has been licensed for use in older adults in the US since December 2009 and in Canada since February 2016. Areas covered: In this review, we summarize postlicensure studies on the immunogenicity, safety, and effectiveness of IIV3-HD and estimates of its cost-effectiveness in older adults. We also discuss the potential application of IIV3-HD in adults 50-64 years of age and in individuals who may respond poorly to standard-dose influenza vaccines. Expert commentary: Multiple studies conducted since 2004 have consistently shown that, in older adults, IIV3-HD induces substantially greater antibody responses and better protection against influenza and influenza-associated hospitalization than IIV3-SD. Health economic analyses suggest that IIV3-HD can be a cost-effective alternative to standard-dose trivalent or quadrivalent inactivated influenza vaccines and can even be cost-saving compared to IIV3-SD in older adults. Further investigation of IIV3-HD vaccination as a way to improve immune responses and protection against influenza in immunocompromised individuals is warranted.

DOI: 10.1080/14760584.2016.1254044
PubMed: 27813430

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000119
to stream Main, to step Curation: 000119

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Fluzone® High-Dose Influenza Vaccine.</title>
<author><name sortKey="Robertson, Corwin A" sort="Robertson, Corwin A" uniqKey="Robertson C" first="Corwin A" last="Robertson">Corwin A. Robertson</name>
<affiliation wicri:level="2"><nlm:affiliation>a Sanofi Pasteur Inc. , Swiftwater , PA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a Sanofi Pasteur Inc. , Swiftwater , PA </wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Diazgranados, Carlos A" sort="Diazgranados, Carlos A" uniqKey="Diazgranados C" first="Carlos A" last="Diazgranados">Carlos A. Diazgranados</name>
<affiliation wicri:level="2"><nlm:affiliation>a Sanofi Pasteur Inc. , Swiftwater , PA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a Sanofi Pasteur Inc. , Swiftwater , PA </wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Decker, Michael D" sort="Decker, Michael D" uniqKey="Decker M" first="Michael D" last="Decker">Michael D. Decker</name>
<affiliation wicri:level="2"><nlm:affiliation>a Sanofi Pasteur Inc. , Swiftwater , PA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a Sanofi Pasteur Inc. , Swiftwater , PA </wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>b Department of Health Policy , Vanderbilt University School of Medicine , Nashville , TN , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b Department of Health Policy , Vanderbilt University School of Medicine , Nashville , TN </wicri:regionArea>
<placeName><region type="state">Tennessee</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chit, Ayman" sort="Chit, Ayman" uniqKey="Chit A" first="Ayman" last="Chit">Ayman Chit</name>
<affiliation wicri:level="2"><nlm:affiliation>a Sanofi Pasteur Inc. , Swiftwater , PA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a Sanofi Pasteur Inc. , Swiftwater , PA </wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>c Leslie Dan Faculty of Pharmacy , University of Toronto , Toronto , Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>c Leslie Dan Faculty of Pharmacy , University of Toronto , Toronto </wicri:regionArea>
<wicri:noRegion>Toronto </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mercer, Monica" sort="Mercer, Monica" uniqKey="Mercer M" first="Monica" last="Mercer">Monica Mercer</name>
<affiliation wicri:level="2"><nlm:affiliation>a Sanofi Pasteur Inc. , Swiftwater , PA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a Sanofi Pasteur Inc. , Swiftwater , PA </wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Greenberg, David P" sort="Greenberg, David P" uniqKey="Greenberg D" first="David P" last="Greenberg">David P. Greenberg</name>
<affiliation wicri:level="2"><nlm:affiliation>a Sanofi Pasteur Inc. , Swiftwater , PA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a Sanofi Pasteur Inc. , Swiftwater , PA </wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>d Department of Pediatrics , University of Pittsburgh School of Medicine , Pittsburgh , PA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>d Department of Pediatrics , University of Pittsburgh School of Medicine , Pittsburgh , PA </wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27813430</idno>
<idno type="pmid">27813430</idno>
<idno type="doi">10.1080/14760584.2016.1254044</idno>
<idno type="wicri:Area/Main/Corpus">000119</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000119</idno>
<idno type="wicri:Area/Main/Curation">000119</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000119</idno>
<idno type="wicri:Area/Main/Exploration">000119</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Fluzone® High-Dose Influenza Vaccine.</title>
<author><name sortKey="Robertson, Corwin A" sort="Robertson, Corwin A" uniqKey="Robertson C" first="Corwin A" last="Robertson">Corwin A. Robertson</name>
<affiliation wicri:level="2"><nlm:affiliation>a Sanofi Pasteur Inc. , Swiftwater , PA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a Sanofi Pasteur Inc. , Swiftwater , PA </wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Diazgranados, Carlos A" sort="Diazgranados, Carlos A" uniqKey="Diazgranados C" first="Carlos A" last="Diazgranados">Carlos A. Diazgranados</name>
<affiliation wicri:level="2"><nlm:affiliation>a Sanofi Pasteur Inc. , Swiftwater , PA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a Sanofi Pasteur Inc. , Swiftwater , PA </wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Decker, Michael D" sort="Decker, Michael D" uniqKey="Decker M" first="Michael D" last="Decker">Michael D. Decker</name>
<affiliation wicri:level="2"><nlm:affiliation>a Sanofi Pasteur Inc. , Swiftwater , PA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a Sanofi Pasteur Inc. , Swiftwater , PA </wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>b Department of Health Policy , Vanderbilt University School of Medicine , Nashville , TN , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b Department of Health Policy , Vanderbilt University School of Medicine , Nashville , TN </wicri:regionArea>
<placeName><region type="state">Tennessee</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chit, Ayman" sort="Chit, Ayman" uniqKey="Chit A" first="Ayman" last="Chit">Ayman Chit</name>
<affiliation wicri:level="2"><nlm:affiliation>a Sanofi Pasteur Inc. , Swiftwater , PA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a Sanofi Pasteur Inc. , Swiftwater , PA </wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>c Leslie Dan Faculty of Pharmacy , University of Toronto , Toronto , Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>c Leslie Dan Faculty of Pharmacy , University of Toronto , Toronto </wicri:regionArea>
<wicri:noRegion>Toronto </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mercer, Monica" sort="Mercer, Monica" uniqKey="Mercer M" first="Monica" last="Mercer">Monica Mercer</name>
<affiliation wicri:level="2"><nlm:affiliation>a Sanofi Pasteur Inc. , Swiftwater , PA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a Sanofi Pasteur Inc. , Swiftwater , PA </wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Greenberg, David P" sort="Greenberg, David P" uniqKey="Greenberg D" first="David P" last="Greenberg">David P. Greenberg</name>
<affiliation wicri:level="2"><nlm:affiliation>a Sanofi Pasteur Inc. , Swiftwater , PA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a Sanofi Pasteur Inc. , Swiftwater , PA </wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>d Department of Pediatrics , University of Pittsburgh School of Medicine , Pittsburgh , PA , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>d Department of Pediatrics , University of Pittsburgh School of Medicine , Pittsburgh , PA </wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Expert review of vaccines</title>
<idno type="eISSN">1744-8395</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antibodies, Viral (blood)</term>
<term>Canada</term>
<term>Cost-Benefit Analysis</term>
<term>Hospitalization</term>
<term>Humans</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (adverse effects)</term>
<term>Influenza Vaccines (economics)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Middle Aged</term>
<term>Product Surveillance, Postmarketing</term>
<term>United States</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Analyse coût-bénéfice</term>
<term>Anticorps antiviraux (sang)</term>
<term>Canada</term>
<term>Grippe humaine ()</term>
<term>Hospitalisation</term>
<term>Humains</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Surveillance post-commercialisation des produits de santé</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (effets indésirables)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins antigrippaux (économie)</term>
<term>États-Unis d'Amérique</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Canada</term>
<term>Cost-Benefit Analysis</term>
<term>Hospitalization</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Product Surveillance, Postmarketing</term>
<term>United States</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Analyse coût-bénéfice</term>
<term>Canada</term>
<term>Grippe humaine</term>
<term>Hospitalisation</term>
<term>Humains</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Surveillance post-commercialisation des produits de santé</term>
<term>États-Unis d'Amérique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>INTRODUCTION</b>
</p>
<p>Fluzone® High-Dose (IIV3-HD) is a trivalent, inactivated, split-virus influenza vaccine indicated for use in older adults (≥65 years of age). It contains 60 µg hemagglutinin of each influenza strain, which is four times the hemagglutinin content of standard-dose influenza vaccines, including Fluzone (IIV3-SD). IIV3-HD has been licensed for use in older adults in the US since December 2009 and in Canada since February 2016. Areas covered: In this review, we summarize postlicensure studies on the immunogenicity, safety, and effectiveness of IIV3-HD and estimates of its cost-effectiveness in older adults. We also discuss the potential application of IIV3-HD in adults 50-64 years of age and in individuals who may respond poorly to standard-dose influenza vaccines. Expert commentary: Multiple studies conducted since 2004 have consistently shown that, in older adults, IIV3-HD induces substantially greater antibody responses and better protection against influenza and influenza-associated hospitalization than IIV3-SD. Health economic analyses suggest that IIV3-HD can be a cost-effective alternative to standard-dose trivalent or quadrivalent inactivated influenza vaccines and can even be cost-saving compared to IIV3-SD in older adults. Further investigation of IIV3-HD vaccination as a way to improve immune responses and protection against influenza in immunocompromised individuals is warranted.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27813430</PMID>
<DateCompleted><Year>2017</Year>
<Month>07</Month>
<Day>31</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>02</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8395</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>15</Volume>
<Issue>12</Issue>
<PubDate><Year>2016</Year>
<Month>12</Month>
</PubDate>
</JournalIssue>
<Title>Expert review of vaccines</Title>
<ISOAbbreviation>Expert Rev Vaccines</ISOAbbreviation>
</Journal>
<ArticleTitle>Fluzone® High-Dose Influenza Vaccine.</ArticleTitle>
<Pagination><MedlinePgn>1495-1505</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="INTRODUCTION">Fluzone® High-Dose (IIV3-HD) is a trivalent, inactivated, split-virus influenza vaccine indicated for use in older adults (≥65 years of age). It contains 60 µg hemagglutinin of each influenza strain, which is four times the hemagglutinin content of standard-dose influenza vaccines, including Fluzone (IIV3-SD). IIV3-HD has been licensed for use in older adults in the US since December 2009 and in Canada since February 2016. Areas covered: In this review, we summarize postlicensure studies on the immunogenicity, safety, and effectiveness of IIV3-HD and estimates of its cost-effectiveness in older adults. We also discuss the potential application of IIV3-HD in adults 50-64 years of age and in individuals who may respond poorly to standard-dose influenza vaccines. Expert commentary: Multiple studies conducted since 2004 have consistently shown that, in older adults, IIV3-HD induces substantially greater antibody responses and better protection against influenza and influenza-associated hospitalization than IIV3-SD. Health economic analyses suggest that IIV3-HD can be a cost-effective alternative to standard-dose trivalent or quadrivalent inactivated influenza vaccines and can even be cost-saving compared to IIV3-SD in older adults. Further investigation of IIV3-HD vaccination as a way to improve immune responses and protection against influenza in immunocompromised individuals is warranted.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Robertson</LastName>
<ForeName>Corwin A</ForeName>
<Initials>CA</Initials>
<AffiliationInfo><Affiliation>a Sanofi Pasteur Inc. , Swiftwater , PA , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>DiazGranados</LastName>
<ForeName>Carlos A</ForeName>
<Initials>CA</Initials>
<AffiliationInfo><Affiliation>a Sanofi Pasteur Inc. , Swiftwater , PA , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Decker</LastName>
<ForeName>Michael D</ForeName>
<Initials>MD</Initials>
<AffiliationInfo><Affiliation>a Sanofi Pasteur Inc. , Swiftwater , PA , USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>b Department of Health Policy , Vanderbilt University School of Medicine , Nashville , TN , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chit</LastName>
<ForeName>Ayman</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>a Sanofi Pasteur Inc. , Swiftwater , PA , USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>c Leslie Dan Faculty of Pharmacy , University of Toronto , Toronto , Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mercer</LastName>
<ForeName>Monica</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>a Sanofi Pasteur Inc. , Swiftwater , PA , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Greenberg</LastName>
<ForeName>David P</ForeName>
<Initials>DP</Initials>
<AffiliationInfo><Affiliation>a Sanofi Pasteur Inc. , Swiftwater , PA , USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>d Department of Pediatrics , University of Pittsburgh School of Medicine , Pittsburgh , PA , USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>11</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Expert Rev Vaccines</MedlineTA>
<NlmUniqueID>101155475</NlmUniqueID>
<ISSNLinking>1476-0584</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000618615">Fluzone High-Dose</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N">Canada</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011358" MajorTopicYN="Y">Product Surveillance, Postmarketing</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Influenza</Keyword>
<Keyword MajorTopicYN="Y">high-dose</Keyword>
<Keyword MajorTopicYN="Y">immunocompromising conditions</Keyword>
<Keyword MajorTopicYN="Y">immunosenescence</Keyword>
<Keyword MajorTopicYN="Y">older adults</Keyword>
<Keyword MajorTopicYN="Y">vaccine</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>11</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>8</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>11</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27813430</ArticleId>
<ArticleId IdType="doi">10.1080/14760584.2016.1254044</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Canada</li>
<li>États-Unis</li>
</country>
<region><li>Pennsylvanie</li>
<li>Tennessee</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Robertson, Corwin A" sort="Robertson, Corwin A" uniqKey="Robertson C" first="Corwin A" last="Robertson">Corwin A. Robertson</name>
</region>
<name sortKey="Chit, Ayman" sort="Chit, Ayman" uniqKey="Chit A" first="Ayman" last="Chit">Ayman Chit</name>
<name sortKey="Decker, Michael D" sort="Decker, Michael D" uniqKey="Decker M" first="Michael D" last="Decker">Michael D. Decker</name>
<name sortKey="Decker, Michael D" sort="Decker, Michael D" uniqKey="Decker M" first="Michael D" last="Decker">Michael D. Decker</name>
<name sortKey="Diazgranados, Carlos A" sort="Diazgranados, Carlos A" uniqKey="Diazgranados C" first="Carlos A" last="Diazgranados">Carlos A. Diazgranados</name>
<name sortKey="Greenberg, David P" sort="Greenberg, David P" uniqKey="Greenberg D" first="David P" last="Greenberg">David P. Greenberg</name>
<name sortKey="Greenberg, David P" sort="Greenberg, David P" uniqKey="Greenberg D" first="David P" last="Greenberg">David P. Greenberg</name>
<name sortKey="Mercer, Monica" sort="Mercer, Monica" uniqKey="Mercer M" first="Monica" last="Mercer">Monica Mercer</name>
</country>
<country name="Canada"><noRegion><name sortKey="Chit, Ayman" sort="Chit, Ayman" uniqKey="Chit A" first="Ayman" last="Chit">Ayman Chit</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000152 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000152 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    GrippeCanadaV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:27813430
   |texte=   Fluzone® High-Dose Influenza Vaccine.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:27813430" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeCanadaV3

This area was generated with Dilib version V0.6.35.
Data generation: Tue Jul 7 13:36:58 2020. Site generation: Sat Sep 26 07:06:42 2020

	Corpus GrippeCanadaV3
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Corpus GrippeCanadaV3

Fluzone® High-Dose Influenza Vaccine.

Fluzone® High-Dose Influenza Vaccine.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki